Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Combination in Relapsed/Refractory Multiple Myeloma with Severe Renal Impairment
NCT02977494Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Jun 2016
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Overall Response Rate at 2 years. Started Jun 2016; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02977494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977494.